An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and One Appendicular Muscle in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)
Phase of Trial: Phase I/II
Latest Information Update: 06 Sep 2018
Price : $35 *
At a glance
- Drugs FLX 787 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Flex Pharma
- 27 Aug 2018 Status changed from recruiting to discontinued as development of Current Formulation has Ceased.
- 18 Jan 2018 Planned initiation date changed from 1 Nov 2017 to 5 Feb 2018.
- 18 Jan 2018 Status changed from not yet recruiting to recruiting.